PharmGKB Demo at U-PGx Summer School
PharmGKB recently held a demonstration of the PharmGKB website as part of the U-PGx Summer School in Bonn, Germany. Continue reading
PharmGKB recently held a demonstration of the PharmGKB website as part of the U-PGx Summer School in Bonn, Germany. Continue reading
The PREPARE study team is proud to announce that the first 2,500 patients have been enrolled for the PREPARE study! Continue reading
The 4th U-PGx Personalized Medicine Day will be organized in Stockholm, Sweden at 18th of June 2018. Continue reading
The U-PGx Summer School will be organized August 20th to 23th in Bonn, Germany. Continue reading
The 3rd U-PGx Personalized Medicine Day in Toulouse was successfully organized and completed on 17th November 2017 with the theme ”Pharmacogenomics in Oncology: Deciphering the Ethical, Legal and Societal Issues”. Continue reading
The PREPARE study team is proud to announce that the first 1,000 patients have been enrolled for the PREPARE study! Continue reading
The tyrosine kinase inhibitor sunitinib is used as first-line therapy in patients with metastasized renal cell carcinoma (mRCC), given in fixed-dose regimens despite its high variability in pharmacokinetics (PKs). Interindividual variability of drug exposure may be responsible for differences in response. Therefore, dosing strategies based on pharmacokinetic/pharmacodynamic (PK/PD) models may be useful to optimize treatment. Continue reading
The 3rd UPGx Personalized Medicine Day will be organized in Toulouse, France. The meeting will be co-organized by the Golden Helix Foundation and the University of Toulouse, both partners of the Ubiquitous Pharmacogenomics (UPGx) project, funded by the European Commission (H2020-668353). Continue reading
On July 21st, 2017, H.E. the United States Ambassador to Greece Mr. Geoffrey Pyatt visited the Laboratory of Molecular Biology and Immunology, University of Patras (UPAT), as part of his visit to academic entities in Patras that produce and offer innovative results and services in the biotechnology and healthcare sectors.
The PREPARE (PREemptive Pharmacogenomic testing for prevention of Adverse drug Reactions) Study has been opened for recruitment! The first patient has been included in Aviano, Italy. Continue reading